Immunomodulatory effects of anti-estrogenic drugs

A. Ray and A. B. Mitra, Estrogen and breast cancer, ICMR Bull. 33 (2003) 13-24.Search in Google Scholar

M. N. Okobia and C. H. Bunker, Epidemiological risk factors for breast cancer - a review, Niger. J. Clin. Pract. 8 (2005) 35-42.Search in Google Scholar

T. Suzuki, Y. Miki, N. Ohuchi and H. Sasano, Intratumoral estrogen production in breast carcinoma: significance of aromatase, Breast Cancer 15 (2008) 270-277; DOI: 10.1007/s12282-008-0062-z.10.1007/s12282-008-0062-zSearch in Google Scholar

I. Czajka-Oraniec and E. R. Simpson, Aromatase research and its clinical significance, Endokrynol. Pol. 61 (2010) 126-134.Search in Google Scholar

W. C. Park and V. C. Jordan, Selective estrogen receptor modulators (SERMs) and their roles in breast cancer prevention, Trends Mol. Med. 8 (2002) 82-88; DOI: 10.1016/S1471-4914(02)02282-7.10.1016/S1471-4914(02)02282-7Search in Google Scholar

G. T. Beatson, On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new treatment with illustrative cases, Lancet 2 (1896) 104-107; DOI: 10.1016/S0140-6736(01)72384-7.10.1016/S0140-6736(01)72384-7Search in Google Scholar

W. R. Miller, Oestrogens and breast cancer: biological considerations, Br. Med. Bull. 47 (1991) 470-483.10.1093/oxfordjournals.bmb.a072485Search in Google Scholar

V. C. Jordan and W. J. Gradishar, Hormonal Therapy for Breast Cancer, in The Cancer Handbook (Ed. M. R. Alison), Vol. 2, Nature Publishing Group, London 2002, pp. 1449-1464.Search in Google Scholar

P. Lonning, C. Pfister, A. Martoni and C. Zamagni, Pharmacokinetics of third-generation aromatase inhibitors, Semin. Oncol. 30 Suppl. 14 (2003) 23-32; DOI: 10.1016/S0093-7754(03)00305-1.10.1016/S0093-7754(03)00305-1Search in Google Scholar

R. Stuart-Harris and A. Davis, Optimal adjuvant endocrine therapy for early breast cancer, Women's Health 6 (2010) 383-398; DOI: 10.2217/whe.10.25.10.2217/WHE.10.2520426605Search in Google Scholar

T. Delozier, Hormonal treatment in breast cancer, J. Gynecol. Obstet. Biol. Reprod. 39, Suppl. 8 (2010) F71-78; DOI: 10.1016/j.jgyn.2010.10.004.10.1016/j.jgyn.2010.10.00421074336Search in Google Scholar

D. P. McDonnell and S. E. Wardell, The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer, Curr. Opin. Pharmacol. 10 (2010) 620-628; DOI: 10.1016/j.coph.2010.09.007.10.1016/j.coph.2010.09.007298161920926342Search in Google Scholar

F. Lumachi, G. Luisetto, S. M. Basso, U. Basso, A. Brunello and V. Camozzi, Endocrine therapy of breast cancer, Curr. Med. Chem. 18 (2011) 513-522; DOI: 10.2174/092986711794480177.10.2174/09298671179448017721143113Search in Google Scholar

A. Thomsen and J. M. Kolesar, Chemoprevention of breast cancer, Am. J. Health Syst. Pharm. 65 (2008) 2221-2228; DOI: 10.2146/ajhp070663.10.2146/ajhp07066319020189Search in Google Scholar

C. Rivera-Guevara and J. Camacho, Tamoxifen and its new derivatives in cancer research, Recent Pat. Anticancer Drug Discov. 6 (2011) 237-245.10.2174/15748921179532848621247404Search in Google Scholar

R. Weinshilboum, Pharmacogenomics of endocrine therapy in breast cancer, Adv. Exp. Med. Biol. 630 (2008) 220-231; DOI: 10.1007/978-0-387-78818-0_14.10.1007/978-0-387-78818-0_1418637494Search in Google Scholar

H. Brauch, T. E. Mürdter, M. Eichelbaum and M. Schwab, Pharmacogenomics of tamoxifen therapy, Clin. Chem. 55 (2009) 1770-1782; DOI: 10.1373/clinchem.2008.121756.10.1373/clinchem.2008.12175619574470Search in Google Scholar

R. Clarke, F. Leonessa, J. N. Welch and T. C. Skaar, Cellular and molecular pharmacology of antiestrogen action and resistance, Pharmacol. Rev. 53 (2001) 25-71.Search in Google Scholar

A. Ring and M. Dowsett, Mechanisms of tamoxifen resistance, Endocr. Relat. Cancer 11 (2004) 643-658; DOI: 10.1677/erc.1.00776.10.1677/erc.1.0077615613444Search in Google Scholar

C. M. Joffroy, M. B. Buck, M. B. Stope, S. L. Popp, K. Pfizenmaier and C. Knabbe, Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer, Cancer Res. 70 (2010) 1314-1322; DOI: 10.1158/0008-5472.CAN-09-3292.10.1158/0008-5472.CAN-09-329220145137Search in Google Scholar

S. Rotstein, H. Blomgren, B. Petrini, J. Wasserman and L. V. von Stedingk, Influence of adjuvant tamoxifen on blood lymphocytes, Breast Cancer Res. Treat. 12 (1988) 75-79; DOI: 10.1007/BF01805743.10.1007/BF018057433196888Search in Google Scholar

E. Robinson, D. Rubin, T. Mekori, R. Segal and S. Pollack, In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer, Cancer Immunol. Immunother. 37 (1993) 209-212; DOI: 10.1007/BF01525437.10.1007/BF015254378334683Search in Google Scholar

P. Mallmann and D. Krebs, Effect of tamoxifen on parameters of cell-mediated immunity in post-menopausal patients with breast carcinoma, Zbl. Gynakol. 113 (1991) 689-696.Search in Google Scholar

J. Lukac, Z. Kusic, D. Kordic, M. Koncar and A. Bolanca, Natural killer cell activity, phagocytosis, and number of peripheral blood cells in breast cancer patients treated with tamoxifen, Breast Cancer Res. Treat. 29 (1994) 279-285; DOI: 10.1007/BF00666482.10.1007/BF006664828049462Search in Google Scholar

M. E. Sabbioni, M. Castiglione, C. Hürny, H. P. Siegrist, M. Bacchi, J. Bernhard, B. Thürlimann, H. Bonnefoi, L. Perey, A. Goldhirsch and H. J. Senn, Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients, Support. Care Cancer 7 (1999) 149-153; DOI: 10.1007/s005200050245.10.1007/s00520005024510335933Search in Google Scholar

E. Baral, E. Nagy, G. V. Krepart, R. J. Lotocki, H. W. Unruh and I. Berczi, Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells, Anticancer Res. 20 (2000) 2027-2031.Search in Google Scholar

E. Baral, E. Nagy, L. Kangas and I. Berczi, Anti-estrogens enhance the therapeutic effect of lymphokine-activated killer cells on the P815 murine mastocytoma, Int. J. Cancer 67 (1996) 580-585; DOI: 10.1002/(SICI)1097-0215(19960807).Search in Google Scholar

E. Baral, E. Nagy, L. Kangas and I. Berczi, Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens, Anticancer Res. 17 (1997) 3653-3658.Search in Google Scholar

S. Kumru, F. M. Yildiz, A. Godekmerdan, S. Kutlu, B. Yilmaz and B. Gurates, Effects of raloxifene and hormone replacement therapy on serum Th2 and Th3 type cytokine concentrations in healthy postmenopausal women: a randomised controlled trial, Arch. Gynecol. Obstet. 277 (2008) 489-493; DOI: 10.1007/s00404-007-0521-3.10.1007/s00404-007-0521-318066566Search in Google Scholar

Y. Zhang, S. Saha, G. Rosenfeld, J. Gonzalez, K. P. Pepeljugoski and E. Peeva, Raloxifene modulates estrogen-mediated B cell autoreactivity in NZB/W F1 mice, J. Rheumatol. 37 (2010) 1646-1657; DOI: 10.3899/jrheum.090911.10.3899/jrheum.09091120551107Search in Google Scholar

G. Nalbandian, V. Paharkova-Vatchkova, A. Mao, S. Nale and S. Kovats, The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation, J. Immunol. 175 (2005) 2666-2675.10.4049/jimmunol.175.4.266616081843Search in Google Scholar

M. A. García-Pérez, R. Del Val, I. Noguera, C. Hermenegildo, B. Pineda, A. Martinez-Romero and A. Cano, Estrogen receptor agonists and immune system in ovariectomized mice, Int. J. Immunopathol. Pharmacol. 19 (2006) 807-819.10.1177/03946320060190041017166402Search in Google Scholar

M. C. Erlandsson, E. Gomori, M. Taube and H. Carlsten, Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice, Cell. Immunol. 205 (2000) 103-109; DOI: 10.1006/cimm.2000.1719.10.1006/cimm.2000.171911104582Search in Google Scholar

H. Masuoka, M. Mori, N. Nomura, M. Sakurai, K. Yoshida, N. Usuda, H. Shirai, I. Shimokawara and K. Asaishi, Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens, Jpn. J. Cancer. Res. 29 (2002) 881-887.Search in Google Scholar

S. M. Haeryfar, E. Nagy, E. Baral, G. V. Krepart, R. J. Lotocki and I. Berczi, Antiestrogens affect both pathways of killer cell-mediated oncolysis, Anticancer Res. 20 (2000) 1849-1853.Search in Google Scholar

J. Komi and O. Lassila, Antioestrogens enhance tumour necrosis factor receptor 2 (TNF-R2) expression and TNF-R2-mediated proliferation in activated T cells, Scand. J. Immunol. 48 (1998) 254-260; DOI: 10.1046/j.1365-3083.1998.00388.x.10.1046/j.1365-3083.1998.00388.x9743209Search in Google Scholar

J. Teodorczyk-Injeyan, M. Cembrzynska-Nowak, S. Lalani and J. A. Kellen, Modulation of biological responses of normal human mononuclear cells by antiestrogens, Anticancer Res. 13 (1993) 279-283.Search in Google Scholar

J. A. Kellen, The effect of toremifene on the expression of some genes in human mononuclear cells, In Vivo 9 (1995) 215-217.Search in Google Scholar

L. S. Järvinen, S. Pyrhönen, K. J. Kairemo and T. Paavonen, The effect of anti-oestrogens on cytokine production in vitro, Scand. J. Immunol. 44 (1996) 15-20; DOI: 10.1046/j.1365-3083.1996.d01-85.x.10.1046/j.1365-3083.1996.d01-85.x8693287Search in Google Scholar

P. Pal, J. K. Kanaujiya, S. Lochab, S. B. Tripathi, M. L. Bhatt, P. K. Singh, S. Sanyal and A. K. Trivedi, 2-D gel electrophoresis-based proteomic analysis reveals that ormeloxifen induces G0-G1 growth arrest and ERK-mediated apoptosis in chronic myeloid leukemia cells K562, Proteomics 11 (2011) 1517-1529; DOI: 10.1002/pmic.201000720.10.1002/pmic.20100072021360677Search in Google Scholar

L. Thomas, M. Asad, H. J. Hrishikeshavan and G. K. Chandrakala, Effect of centchroman on cellular and humoral immunity, Indian J. Physiol. Pharmacol. 51 (2007) 387-394.Search in Google Scholar

A. Purohit, A. Singh, M. W. Ghilchik, O. Serlupi-Crescenzi and M. J. Reed, Inhibition of IL-6+ IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts, Br. J. Cancer 88 (2003) 630-635; DOI: 10.1038/sj.bjc.6600785.10.1038/sj.bjc.6600785237716412592380Search in Google Scholar

P. G. Morris, C. A. Hudis, D. Giri, M. Morrow, D. J. Falcone, X. K. Zhou, B. Du, E. Brogi, C. B. Crawford, L. Kopelovich, K. Subbaramaiah and A. J. Dannenberg, Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer, Cancer Prev. Res. 4 (2011) 1021-1029; DOI: 10.1158/1940-6207.CAPR-11-0110.10.1158/1940-6207.CAPR-11-0110313142621622727Search in Google Scholar

J. Berry, B. J. Green and D. S. Matheson, Modulation of natural killer cell activity in stage I post-menopausal breast cancer patients on low-dose aminoglutethimide, Cancer Immunol. Immunother. 24 (1987) 72-75; DOI: 10.1007/BF00199836.10.1007/BF001998363815420Search in Google Scholar

H. van Dijk and H. E. Jacobse-Geels, Evidence for the involvement of corticosterone in the ontogeny of the cellular immune apparatus of the mouse, Immunology 35 (1978) 637-642.Search in Google Scholar

M. D. Coleman, L. F. Khalaf and P. J. Nicholls, Aminoglutethimide-induced leukopenia in a mouse model: effects of metabolic and structural determinants, Environ. Toxicol. Pharmacol. 15 (2003) 27-32; DOI: 10.1016/j.etap.2003.08.003.10.1016/j.etap.2003.08.003Search in Google Scholar

M. J. Cannon, M. G. Petroff and J. L. Pate, Effects of prostaglandin F2alpha and progesterone on the ability of bovine luteal cells to stimulate T lymphocyte proliferation, Biol. Reprod. 69 (2003) 695-700; DOI: 10.1095/?biolreprod.103.017590.10.1095/biolreprod.103.017590Search in Google Scholar

D. P. Braun, K. A. Crist, F. Shaheen, E. D. Staren, S. Andrews and J. Parker, Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity, Am. J. Surg. 190 (2005) 570-571; DOI: 10.1016/j.amjsurg.2005.06.013.10.1016/j.amjsurg.2005.06.013Search in Google Scholar

C. P. Schneider, E. A. Nickel, T. S. Samy, M. G. Schwacha, W. G. Cioffi, K. I. Bland and I. H. Chaudry, The aromatase inhibitor, 4-hydroxyandrostenedione, restores immune responses following trauma-hemorrhage in males and decreases mortality from subsequent sepsis, Shock 14 (2000) 347-353.10.1097/00024382-200014030-00019Search in Google Scholar

J. Morales-Montor, C. Hallal-Calleros, M. C. Romano and R. T. Damian, Inhibition of p-450 aromatase prevents feminisation and induces protection during cysticercosis, Int. J. Parasitol. 32 (2002) 1379-1387; DOI: 10.1016/S0020-7519(02)00130-3.10.1016/S0020-7519(02)00130-3Search in Google Scholar

T. Watanabe, M. Sano, M. Toi, T. Saeki, K. Kanda, S. Miura, H. Inaji, H. Sono, H. Saeki, R. Nishimura and Y. Fujita, Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents, Gan. To. Kagaku. Ryoho. (Cancer & Chemotherapy) 29 (2002) 1211-1221.Search in Google Scholar

M. Mello-Grand, V. Singh, C. Ghimenti, M. Scatolini, L. Regolo, E. Grosso, A. Zambelli, G. A. Da Prada, L. Villani, V. Fregoni, P. Baiardi, S. Marsoni, W. R. Miller, A. Costa and G. Chiorino, Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer, Breast Cancer Res. Treat. 121 (2010) 399-411; DOI: 10.1007/s10549-010-0887-y.10.1007/s10549-010-0887-y20428938Search in Google Scholar

B. Karagöz, O. Bilgi, A. Alacacioğlu, A. Ozgün, O. Sayan, A. A. Erikçi and E. G. Kandemir, Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer, Med. Oncol. 27 (2010) 199-202; DOI: 10.1007/s12032-009-9191-2.10.1007/s12032-009-9191-219263253Search in Google Scholar

D. Generali, G. Bates, A. Berruti, M. P. Brizzi, L. Campo, S. Bonardi, A. Bersiga, G. Allevi, M. Milani, S. Aguggini, L. Dogliotti, A. H. Banham, A. L. Harris, A. Bottini and S. B. Fox, Immuno-modulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients, Clin. Cancer Res. 15 (2009) 1046-1051; DOI: 10.1158/1078-0432.CCR-08-1507.10.1158/1078-0432.CCR-08-150719188178Search in Google Scholar

Q. Zhang, D. Tang and H. Zhao, Immunological therapies can relieve aromatase inhibitor-reated joint symptoms in breast cancer survivors, Am. J. Clin. Oncol. 33 (2010) 557-560; DOI: 10.1097/COC.0b013e3181cae782.10.1097/COC.0b013e3181cae78220124972Search in Google Scholar

J. Wang, Q. Zhang, S. Jin, M. Feng, X. Kang, S. Zhao, S. Liu and W. Zhao, Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis, Exp. Gerontol. 44 (2009) 398-405; DOI: 10.1016/j.exger.2009.03.003.10.1016/j.exger.2009.03.00319298850Search in Google Scholar

M. N. Singh, P. L. Martin-Hirsch and F. L. Martin, The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century, Med. Sci. Monit. 14 (2008) 144-148.Search in Google Scholar

J. Komi and O. Lassila, Nonsteroidal anti-estrogens inhibit the functional differentiation of human monocyte-derived dendritic cells, Blood 95 (2000) 2875-2882.10.1182/blood.V95.9.2875.009k12_2875_2882Search in Google Scholar

J. Komi, M. Möttönen, R. Luukkainen and O. Lassila, Non-steroidal anti-oestrogens inhibit the differentiation of synovial macrophages into dendritic cells, Rheumatology 40 (2001) 185-191; DOI: 10.1093/rheumatology/40.2.185.10.1093/rheumatology/40.2.18511257155Search in Google Scholar

S. Behjati and M. H. Frank, The effects of tamoxifen on immunity, Curr. Med. Chem. 16 (2009) 3076-3080.10.2174/092986709788803042290298219689284Search in Google Scholar

B. F. Bebo Jr, B. Dehghani, S. Foster, A. Kurniawan, F. J. Lopez and L. S. Sherman, Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis, Glia 57 (2009) 777-790; DOI: 10.1002/glia.20805.10.1002/glia.20805266720919031437Search in Google Scholar

D. Sereda and V. P. Werth, Improvement in dermatomyositis rash associated with the use of antiestrogen medication, Arch. Dermatol. 142 (2006) 70-72.Search in Google Scholar

M. Babina, F. Kirn, D. Hoser, D. Ernst, W. Rohde, T. Zuberbier and M. Worm, Tamoxifen counteracts the allergic immune response and improves allergen-induced dermatitis in mice, Clin. Exp. Allergy 40 (2010) 1256-1265; DOI: 10.1111/j.1365-2222.2010.03472.x.10.1111/j.1365-2222.2010.03472.x20337649Search in Google Scholar

W. M. Wu, J. L. Suen, B. F. Lin and B. L. Chiang, Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr/lpr mice, Immunology 100 (2000) 110-118; DOI: 10.1046/j.1365-2567.2000.00998.x.10.1046/j.1365-2567.2000.00998.x232698210809966Search in Google Scholar

W. M. Wu, B. F. Lin, Y. C. Su, J. L. Suen and B. L. Chiang, Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB/W F1 mice, Scand. J. Immunol. 52 (2000) 393-400; DOI: 10.1046/j.1365-3083.2000.00789.x.10.1046/j.1365-3083.2000.00789.x11013011Search in Google Scholar

Z. M. Sthoeger, H. Zinger and E. Mozes, Beneficial effects of the anti-oestrogentamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies, Ann. Rheum. Dis. 62 (2003) 341-346; DOI: 10.1136/ard.62.4.341.10.1136/ard.62.4.341175451312634234Search in Google Scholar

E. Peeva, J. Venkatesh and B. Diamond, Tamoxifen blocks estrogen-induced B cell maturation but not survival, J. Immunol. 175 (2005) 1415-1423.10.4049/jimmunol.175.3.141516034077Search in Google Scholar

Y. Y. Dhaher, B. D. Greenstein, M. A. Khamashta and G. R. Hughes, Effects of oestradiol and the oestrogen antagonist Ici 182,780 on the delayed type hypersensitivity (DTH) index and on serum levels of IgM and IgG in ovariectomisedBalb/C and MRL/Mp-Lpr/Lpr mice, a model of systemic lupus erythematosus (SLE), Autoimmunity 33 (2001) 237-243.10.1080/08916934.2002.1187370028561621Search in Google Scholar

V. Paharkova-Vatchkova, R. Maldonado and S. Kovats, Estrogen preferentially promotes the differentiation of CD11c+ CD11b(intermediate) dendritic cells from bone marrow precursors, J. Immunol. 172 (2004) 1426-1436.10.4049/jimmunol.172.3.1426Search in Google Scholar

S. Cuzzocrea, S. Bruscoli, C. Crisafulli, E. Mazzon, M. Agostini, C. Muià, E. Esposito, R. Di Virgilio, R. Meli, E. Vegeto, A. Maggi and C. Riccardi, Estrogen receptor antagonist fulvestrant (ICI 182,780) inhibits the anti-inflammatory effect of glucocorticoids, Mol. Pharmacol. 71 (2007) 132-144; DOI: 10.1124/mol.106.029629.10.1124/mol.106.029629Search in Google Scholar

N. I. Abdou, V. Rider, C. Greenwell, X. Li and B. F. Kimler, Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial, J. Rheumatol. 35 (2008) 797.Search in Google Scholar

S. N. Umathe, P. V. Dixit, M. M. Wanjari and M. P. Ullewar, Leuprolide—a GnRH agonist—prevents restraint stress-induced immunosuppression via sex steroid-independent peripheral mechanism in mice, Int. Immunopharmacol. 8 (2008) 71-79; DOI: 10.1016/j.intimp.2007.10.011.10.1016/j.intimp.2007.10.011Search in Google Scholar

G. L. Goldberg, C. G. King, R. A. Nejat, D. Y. Suh, O. M. Smith, J. C. Bretz, R. M. Samstein, J. A. Dudakov, A. P. Chidgey, S. Chen-Kiang, R. L. Boyd and M. R. van den Brink, Luteinizing hormone-releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation, J. Immunol. 182 (2009) 5846-5854; DOI: 10.4049/?jimmunol.0801458.10.4049/jimmunol.0801458Search in Google Scholar

K. Szyllo, H. Tchorzewski, M. Banasik, E. Glowacka, P. Lewkowicz and A. Kamer-Bartosinska, The involvement of T lymphocytes in the pathogenesis of endometriotic tissues overgrowth in women with endometriosis, Mediators Inflamm. 12 (2003) 131-138; DOI: 10.1080/0962935031000134842.10.1080/0962935031000134842Search in Google Scholar

H. N. Ho, H. F. Chen, S. U. Chen, K. H. Chao, Y. S. Yang, S. C. Huang, T. Y. Lee and T. J. Gill 3rd., Gonadotropin releasing hormone (GnRH) agonist induces down-regulation of the CD3+ CD25+ lymphocyte subpopulation in peripheral blood, Am. J. Reprod. Immunol. 33 (1995) 243-252.10.1111/j.1600-0897.1995.tb00891.xSearch in Google Scholar

N. Umesaki, T. Tanaka, M. Miyama, K. Mizuno, N. Kawamura and S. Ogita, Increased natural killer cell activities in patients treated with gonadotropin releasing hormone agonist, Gynecol. Obstet. Invest. 48 (1999) 66-68; DOI: 10.1159/000010137.10.1159/000010137Search in Google Scholar

G. G. Garzetti, A. Ciavattini, M. Provinciali, M. Muzzioli, G. Di Stefano and N. Fabris, Natural cytotoxicity and GnRH agonist administration in advanced endometriosis: positive modulation on natural killer activity, Obstet. Gynecol. 88 (1996) 234-240; DOI: 10.1016/0029-7844(96)00146-9.10.1016/0029-7844(96)00146-9Search in Google Scholar

M. E. Sabbioni, H. P. Siegrist, M. Bacchi, J. Bernhard, M. Castiglione, B. Thürlimann, H. Bonnefoi, L. Perey, R. Herrmann, A. Goldhirsch and C. Hürny, Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment, Breast Cancer Res. Treat. 59 (2000) 279-287; DOI: 10.1023/A:1006379925343.10.1023/A:1006379925343Search in Google Scholar

A. Ray, V. Gupta, R. Kant, R. Yadav, A. K. Bahadur, S. L. D. Naik, B. K. Sharma and N. S. Murthy, T-lymphocytes in breast cancer: association with prognostic factors and response to treatment, Ann. Natl. Acad. Med. Sci. 39 (2003) 105-115.Search in Google Scholar

E. Pavoni, G. Monteriù, D. Santapaola, F. Petronzelli, A. M. Anastasi, A. Pelliccia, V. D'Alessio, R. De Santis and O. Minenkova, Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells, BMC. Biotechnol. 7 (2007) 70; DOI: 10.1186/1472-6750-7-70.10.1186/1472-6750-7-70217550617945015Search in Google Scholar

V. N. Kristensen, C. J. Vaske, J. Ursini-Siegel, P. Van Loo, S. H. Nordgard, R. Sachidanandam, T. Sørlie, F. Wärnberg, V. D. Haakensen, A. Helland, B. Naume, C. M. Perou, D. Haussler, O. G. Troyanskaya and A. L. Børresen-Dale, Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling, Proc. Natl. Acad. Sci. U.S.A. 109 (2012) 2802-2807; DOI: 10.1073/pnas.1108781108.10.1073/pnas.1108781108328699221908711Search in Google Scholar

S. C. Baumgarten and J. Frasor, Mini review: Inflammation: An instigator of more aggressive estrogen receptor (ER) positive breast cancers, Mol. Endocrinol. 26 (2012) 360-371; DOI: 10.1210/me.2011-1302.10.1210/me.2011-1302328619222301780Search in Google Scholar

C. K. Osborne and R. Schiff, Mechanisms of endocrine resistance in breast cancer, Annu. Rev. Med. 62 (2011) 233-247; DOI: 10.1146/annurev-med-070909-182917.10.1146/annurev-med-070909-182917365664920887199Search in Google Scholar

M. E. Grossmann, A. Ray, K. J. Nkhata, D. A. Malakhov, O. P. Rogozina, S. Dogan and M. P. Cleary, Obesity and breast cancer: status of leptin and adiponectin in pathological processes, Cancer Metastasis Rev. 29 (2010) 641-653; DOI: 10.1007/s10555-010-9252-1.10.1007/s10555-010-9252-120821253Search in Google Scholar

H. S. Kim, C. K. Yom, H. J. Kim, J. W. Lee, J. H. Sohn, J. H. Kim, Y. L. Park and S. H. Ahn, Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy, Breast Cancer Res. Treat. 121 (2010) 777-788; DOI: 10.1007/s10549-009-0560-5.10.1007/s10549-009-0560-519806450Search in Google Scholar